.jpg)
.png)
All
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to... more
Telemedicine is Here to Stay Telemedicine is a valuable tool for patient care, but one that has been underused and underdeveloped for many years. When COVID-19 interrupted daily life as we knew it, telemedicine abruptly entered the mainstream of healthcare. It is estimated that provider networks... more
It is well-established that, compared to men, post-menopausal women enjoy a degree of protection against atherosclerotic cardiovascular disease (ASCVD).1 The rate of ASCVD in post-menopausal women matches or even exceeds that in men.1 In spite of the pre-menopausal protection for women,... more
The SELA board decided to devote this issue of Lipid Spin to the problem of statin intolerance. In formal clinical trials statin intolerance is reported in 2 to 3 percent of study subjects, but longer term follow up studies report a more realistic rate of 15 to 20 percent. In an informal survey of... more
Today the European Atherosclerosis Society released a new consensus position paper on the polygenic nature of hypertriglyceridaemia. It is published in The Lancet, and will available free to download for a period of one month, until February 28. To download the paper, please follow the link: http... more
Introduction While atherosclerotic cardiovascular disease (ASCVD) and dyslipidemia affect all populations, their impact is far from uniform. Many interwoven factors, including genetics, sociocultural determinants, and environmental exposures, create a diverse picture of risk across different... more
Introduction Familial hypercholesterolemia (FH) and type 1 diabetes (T1D) are characterized by significant morbidity and premature mortality. Lipoprotein(a) [Lp(a)], an independent cardiovascular disease (CVD) risk factor, is considered a risk enhancer. Because FH, T1D and elevated levels of Lp... more
Dr. Ziajka, it is very impressive that you have been an investigator of numerous clinical trials, an author of dozens of journal articles and books, an editorial board member of JCL, as well as running the only medical practice in the state Florida devoted exclusively to lipid disorders. Of all the... more
The 2013 NLA Annual Scientific Sessions were held May 29-June 2, 2013 in Las Vegas, NV. Read meeting coverage from selected sessions and presentations here.